Acceleron Announces Change to Executive Management Team
23 Enero 2020 - 3:15PM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics to treat serious and rare diseases, announced today
that John Quisel, J.D., Ph.D, Executive Vice President and Chief
Business Officer, is leaving the Company to become Chief Executive
Officer of a venture-backed startup biotechnology company. Dr.
Quisel’s departure from Acceleron is effective as of February
24.
“John has been a valued colleague and trusted leader at
Acceleron, contributing meaningfully to the Company’s growth and
success,” said Habib Dable, President and Chief Executive Officer
of Acceleron. “During his nearly 14 years here, John has lent his
scientific, business, and legal acumen to many important corporate
initiatives. I’ve personally enjoyed working alongside him and am
delighted for him to take this next natural step in his
career.”
Dr. Quisel joined Acceleron in 2006 and has held a variety of
roles spanning legal, intellectual property, business development
and corporate strategy. During his time with the organization, he
supported venture capital financings, the company’s 2013 initial
public offering, subsequent public offerings, and a range of
collaboration and licensing agreements, including Acceleron’s
longstanding development and commercialization agreements with
Celgene Corp., now Bristol-Myers Squibb.
“I’m enormously grateful for my time at Acceleron and proud of
all that we accomplished throughout the years,” said Dr. Quisel.
“Although my decision to depart was a difficult one, the
opportunity to lead another organization on what I believe will be
a similarly successful path was too enticing to ignore. I leave
Acceleron with cherished memories and the knowledge that the
Company is on the right track, steered by a talented leadership
team.”
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. The Company's leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
Acceleron and its global collaboration partner, Bristol-Myers
Squibb, are co-promoting newly approved REBLOZYL®
(luspatercept-aamt), the first and only approved erythroid
maturation agent, in the United States and are developing
luspatercept for the treatment of chronic anemia in myelodysplastic
syndromes and myelofibrosis. Acceleron is also advancing its
neuromuscular program with ACE-083, a locally-acting Myostatin+
agent in Phase 2 development in Charcot-Marie-Tooth disease and is
conducting a Phase 2 pulmonary program with sotatercept in
pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200123005795/en/
Acceleron Pharma Inc. Investors: Todd James, (617) 649-9393 Vice
President, Investor Relations and Corporate Communications
or
Ed Joyce, 617-649-9242 Director, Investor Relations
or
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024